Vaidya Sane Ayurved Laboratories Limited's Board of Directors, at its meeting held on 15 May 2026, approved the audited standalone and consolidated financial results for the half year and year ended March 31, 2026, alongside several key corporate actions including the acquisition of Parasnath Healthcare (OPC) Private Limited. The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors issued an unmodified opinion on the audited financial results.

Standalone Financial Performance

Vaidya Sane Ayurved Laboratories delivered a steady performance for the year ended March 31, 2026 on a standalone basis. Revenue from operations rose to ₹9,962.27 lakhs from ₹8,711.03 lakhs in the previous year, while total income stood at ₹10,181.00 lakhs compared to ₹8,885.25 lakhs previously. The company reported a profit before tax of ₹608.86 lakhs against ₹686.79 lakhs in the prior year.

The following table summarises the standalone financial performance:

Standalone Half-Year Performance

For the half year ended March 31, 2026, the company reported revenue from operations of ₹5,243.70 lakhs and a net profit of ₹171.07 lakhs, compared to revenue of ₹4,609.53 lakhs and net profit of ₹253.51 lakhs for the half year ended March 31, 2025.

Consolidated Financial Performance

On a consolidated basis, Vaidya Sane Ayurved Laboratories reported revenue from operations of ₹10,690.64 lakhs for the year ended March 31, 2026, compared to ₹8,992.29 lakhs in the prior year. Total consolidated income stood at ₹10,927.41 lakhs. Profit before tax was ₹1,080.56 lakhs against ₹989.38 lakhs previously, while net profit for the year was ₹898.95 lakhs compared to ₹715.39 lakhs.

Acquisition of Parasnath Healthcare

The Board approved the acquisition of 100% shares of Parasnath Healthcare (OPC) Private Limited, a company engaged in operating and managing speciality healthcare services focused on knee pain and clinic-related services, including franchisee clinic operations. The acquisition is subject to completion of closing conditions as specified in the Definitive Acquisition Agreement.

The objective of the acquisition is strategic business expansion, consolidation of franchisee clinic operations, and strengthening the company's presence in the healthcare and speciality clinic segment. The transaction is being undertaken on an arm's-length basis and does not fall within related party transactions.

Other Board Decisions

The Board also approved several other key matters at the meeting:

• Secretarial Auditor Appointment: M/s. Deep Shukla & Associates, Practicing Company Secretary, Mumbai (Membership No: 5652 & Certificate of Practice Number: 5364) appointed as Secretarial Auditor for FY 2026-27.
• Internal Auditor Appointment: M/s. Khare Deshmukh & Co., Chartered Accountants, Pune (Firm Registration Number: 116141W) appointed as Internal Auditor for FY 2026-27.
• Related Party Transactions: The Board approved Related Party Transactions subject to applicable provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.
• Deviation/Variation Certificate: The Board approved filing of Deviation/Variation Certificate(s) in compliance with applicable SEBI regulations. The company confirmed full utilisation of funds raised through a Preferential Issue of Convertible Share Warrants, with the amount fully utilised in September 2025.
• Aaharshastra Foodz Private Limited: The Board noted and approved matters relating to Aaharshastra Foodz Private Limited, a subsidiary of the company.

IPO Proceeds Utilisation

The company had issued and allotted 27,71,200 equity shares of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2,022.98 lakhs. The net issue proceeds after excluding expenses amounted to ₹1,972.98 lakhs. Full utilisation details are as follows:

Earnings Conference Call

Vaidya Sane Ayurved Laboratories has scheduled an Earnings Conference Call to discuss its operational and financial performance for H2 & FY26 on Monday, 18 May 2026 at 12:00 PM. Key management personnel participating include Dr. Rohit Madhav Sane (Chairman & Managing Director), Dr. Vidyut Bipin Ghag (Whole Time Director), and Mr. Narendra Pawar (Chief Financial Officer). Investors may participate through the following dial-in numbers:

Participants may also register via the Diamond Pass Link: https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6739555&linkSecurityString=3816adbee0 . For RSVP and further queries, stakeholders may contact Mr. Rupesh Rege at Adfactors PR on +91 95949 18891. The filing was signed by Sapna Vaishnav, Company Secretary and Compliance Officer.